New article: A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. https://t.co/Ec9OTf90qJ #uterinecancer #oncology htt
906 followers
6,257 followers
RT @DrGattiMays: A phase I study #durvalumab plus #olaparib in recurrent #breastcancer and #ovariancancer #JITC Nicely done Dr Zimmer! @a…
19,673 followers
RT @NCICCR_WMB: Promising phase 1 results from novel #immunotherapy combination therapy for #BreastCancer and #ovariancancer in #clinicaltr…
19 followers
RT @NCICCR_WMB: Promising phase 1 results from novel #immunotherapy combination therapy for #BreastCancer and #ovariancancer in #clinicaltr…